Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pyelonephritis Clear all
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

NCT03840148
View directory record Official record
Conditions
Urinary Tract Infections, Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam), Meropenem
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 21, 2026, 10:58 AM EDT
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01595438
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

NCT00921024
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
CXA-101, Ceftazidime
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jul 21, 2026, 10:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study

NCT07579312
View directory record Official record
Conditions
Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis, Epiploic Appendagitis
Interventions
TruNAV, an RNA-based blood test for host immune activation by infections
Diagnostic Test
Lead sponsor
True Bearing Diagnostics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

NCT01345929
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
CXA-201, Levofloxacin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT04979806
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
Cefepime-zidebactam (FEP-ZID), Meropenem
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT06059846
View directory record Official record
Conditions
Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

NCT01281462
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
La Mesa, California • San Diego, California • Pensacola, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Jul 21, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in Complicated Urinary Tract Infection

NCT01381549
View directory record Official record
Conditions
Infections, Urinary Tract
Interventions
GSK2251052, imipenem-cilastatin, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Preventing Urinary Tract Infection Post-Surgery

NCT01346774
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cranberry powder capsules, Placebo powder capsules
Drug
Lead sponsor
Betsy Foxman
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03788967
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
La Mesa, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Management of Sub-Clinical Bacteriuria in Pregnancy

NCT03275623
View directory record Official record
Conditions
Cystitis, Cystitis;Puerperium, Pyelonephritis
Interventions
Antibiotic, Standard Prenatal Care
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 21, 2026, 10:58 AM EDT
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

NCT04700787
View directory record Official record
Conditions
Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
Interventions
Sulopenem
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
12 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

NCT03687255
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
cefepime/AAI101 combination, Piperacillin/tazobactam
Drug
Lead sponsor
Allecra
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anaheim, California • Buena Park, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 21, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis

NCT01641029
View directory record Official record
Conditions
Pyelonephritis
Interventions
No intervention
Other
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT03230838
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 21, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

The Validity of the Quick Renal MRI in Pediatric Kidney Disease

NCT03959163
View directory record Official record
Conditions
Pyelonephritis, Pyelonephritis Acute, Renal Sclerosis
Interventions
Quick MRI
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 21, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

NCT02753946
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)

NCT06526884
View directory record Official record
Conditions
Pneumonia, Syncope, Congestive Heart Failure, Cellulitis, Pyelonephritis, AKI - Acute Kidney Injury, Diabetic Foot Infection, Osteomyelitis
Interventions
Next Day Clinic
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 21, 2026, 10:58 AM EDT